BFM
MRNS

Boothbay Fund Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Boothbay Fund Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-185,996
Closed -$327K – 2046
2024
Q3 		$327K Hold
185,996
– – 0.01% 1180
2024
Q2 		$218K Buy
185,996
+44,783
+32% +$112K 0.01% 1263
2024
Q1 		$1.28M Sell
141,213
-20,459
-13% -$199K 0.02% 670
2023
Q4 		$1.76M Sell
161,672
-292,200
-64% -$2.19M 0.04% 538
2023
Q3 		$3.65M Buy
453,872
+40,661
+10% +$338K 0.09% 313
2023
Q2 		$4.49M Buy
413,211
+392,297
+1,876% +$3.36M 0.1% 251
2023
Q1 		$144K Sell
20,914
-3,013
-13% -$18.9K ﹤0.01% 1833
2022
Q4 		$95.2K Buy
+23,927
New +$118K ﹤0.01% 1798
2020
Q1 		– Sell
-2,500
Closed -$22K – 1119
2019
Q4 		$22K Buy
+2,500
New +$14K ﹤0.01% 821
2017
Q3 		– Sell
-7,866
Closed -$43K – 808
2017
Q2 		$43K Hold
7,866
– – 0.01% 635
2017
Q1 		$56K Sell
7,866
-11,800
-60% -$63.4K 0.01% 696
2016
Q4 		$79 Buy
19,666
+6,558
+50% +$30.5K 0.02% 694
2016
Q3 		$95K Buy
+13,108
New +$88.6K 0.02% 645
2016
Q1 		– Sell
-2,815
Closed -$86K – 580
2015
Q4 		$86K Buy
+2,815
New +$82.6K 0.04% 513

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boothbay Fund Management's MRNS Position: Q4 2024 in Review

Boothbay Fund Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 185,996 shares — an estimated $327K sold.

Boothbay Fund Management first reported a position in MRNS in Q4 2015 and held it in 14 quarters. The position peaked at $4.49M in Q2 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Boothbay Fund Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 185,996 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $327K.
  • Boothbay Fund Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2015 and held it in 14 quarters.
  • Boothbay Fund Management's Marinus Pharmaceuticals, Inc position peaked at $4.49M in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Boothbay Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.